Evidence map›Paper›PMID 35727933›Full record

ArticleAdvances in gerontology = Uspekhi gerontologii2022

[A new paradigm for the development of neurodegenerative diseases on the example of Alzheimer's disease and Parkinson's disease.]

I V Litvinenko, V Y Lobzin

Open access · bronzeAbstract read
In one paragraph

Article in Advances in gerontology = Uspekhi gerontologii, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

I V LitvinenkoS.M.Kirov Military-Medical Academy, 6 Academician Lebedev str., St. Petersburg 194044, Russian Federation, e-mail: litvinenkoiv@rambler.ru.
V Y LobzinS.M.Kirov Military-Medical Academy, 6 Academician Lebedev str., St. Petersburg 194044, Russian Federation, e-mail: litvinenkoiv@rambler.ru.
S. M. Kirov Military Medical Academy · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of neuronal inflammation developing during the formation of amyloid plaques and Lewy bodies has been investigated. The influence of various exogenous and endogenous factors on the development of neuroinflammation has been established, but the role of various infectious agents in the development of this process has been much less studied. Today, the existence of a universal trigger mechanism of the neurodegenerative process is obvious: a specific pathogen of a bacterial or viral nature (including a long-term persistent in the nervous tissue in a latent state), reactivating, penetrates into certain cerebral structures, where it is influenced by either Aβ or resident macrophages of the central nervous system, which, in turn, are activated and induce the release of pro-inflammatory cytokines, leading to the development of neuronal inflammation, autophagy and neurodegeneration. Reactivation of latent, such as herpes, infection in individuals who are carriers of APOE4 significantly increases the risk of developing Alzheimer's disease. Class II genes of the HLA locus (HLA II) may be related to the progression of neurodegenerative diseases. The increase in iron levels in the glia is induced by inflammation, which leads to neurodegeneration. Disruption of the homeostasis of redox-active metals, iron and copper, is an integral part of the pathogenesis of Alzheimer's disease and Parkinson's disease. The developing neuroinflammation leads to the intensification of the processes of peroxidation, oxidation of metals and the development of ferroptosis.

Indexed as

Alzheimer DiseaseNeurodegenerative DiseasesParkinson DiseaseHumansInflammationIronIronAlzheimer's diseaseAPOECOVID-19ferroptosismicroglianeurodegenerationneuroinflammationParkinson's disease

Identifiers

PMID35727933
PMCPMC9774074
OpenAlexW4286828696

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.